Business
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors design
About this update from Aura Biosciences, Inc.
[{"type":"image","alt":"Aura Biosciences, Inc.","displaySize":"","headline":null,"caption":"Aura Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/2592eb91327180eb73f99563eef568ed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RpQ.Kwi2idocWRj8CXL8ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/2592eb91327180eb73f99563eef568ed","width":300,"height":76},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/RpQ.Kwi2idocWRj8CXL8ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/2592eb91327180eb73f99563eef568ed","width":300,"height":76}},"lazy":false},{"type":"text","content":"Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data","length":93,"tagName":"p"},{"type":"text","content":"Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors","length":99,"tagName":"p"},{"type":"text","content":"Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028","length":132,"tagName":"p"},{"type":"text","content":"BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.","length":321,"tagName":"p"},{"type":"text","content":"“We are entering a pivotal period for Aura as we advance our Phase 3 CoMpass trial toward enrollment completion and potential registration,” said Natalie Holles, Chief Executive Officer of Aura Biosciences. “Bel-sar has the potential to become the first frontline, vision-preserving therapy for patients with early choroidal melanoma, and we are on track to deliver topline data from the CoMpass trial in the second half of 2027. Supported by our strengthened balance sheet, we are focused on executing against these priorities and translating this progress into long-term value for patients and shareholders.”","length":610,"tagName":"p"},{"type":"text","content":"Recent Pipeline Developments ","length":28,"tagName":"p"},{"type":"text","content":"Ear...